Literature DB >> 19228103

Levodopa-related wearing-off in Parkinson's disease: identification and management.

Rajesh Pahwa1, Kelly E Lyons.   

Abstract

BACKGROUND: Levodopa is currently the most effective treatment for Parkinson's disease (PD); however, long-term levodopa therapy often results in motor complications, such as motor fluctuations and dyskinesia. The initial complication is commonly wearing-off, which is the re-emergence of motor and non-motor symptoms before the next scheduled levodopa dose.
OBJECTIVE: The purpose of this article was to review published literature that discusses wearing-off, focusing on the role of the healthcare professional, including the primary care physician, in the effective management of wearing-off.
METHODS: An electronic literature search was conducted using MEDLINE and EMBASE to find articles discussing wearing-off and its management using the following keywords: 'Parkinson's disease'; 'wearing-off'; 'levodopa'; 'primary care'. FINDINGS AND
CONCLUSIONS: Current evidence indicates that a consistent delivery of levodopa should improve long-term symptomatic efficacy and may prevent or delay motor complications. A number of therapeutic options are available to optimize therapeutic outcome, including modification of the levodopa dose or dosing schedule,switching to another levodopa formulation and the use of adjunct therapies, such as catechol-O-methyl transferase inhibitors, dopamine agonists and monoamine oxidase-B inhibitors. The management of wearing-off is dependent upon the early identification of symptoms and the initiation of effective treatment. Key issues are the need to educate patients and to facilitate good communication with both primary and secondary healthcare professionals. In most cases, patients with PD initially present to primary healthcare professionals who may refer the patient to a neurologist once disease management becomes more complex. However, in many cases, especially in rural areas where neurologists may not be widely available, the primary healthcare professionals may manage the patient throughout the disease course. Limitations of this review include the restricted search criteria and selected search period.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228103     DOI: 10.1185/03007990902779319

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  16 in total

1.  Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.

Authors:  Domiziana Rinaldi; Francesca Assogna; Michela Sforza; Stefania Tagliente; Francesco E Pontieri
Journal:  Neurol Sci       Date:  2017-09-27       Impact factor: 3.307

2.  RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.

Authors:  Katelin E Ahlers-Dannen; Mackenzie M Spicer; Rory A Fisher
Journal:  Mol Pharmacol       Date:  2020-02-03       Impact factor: 4.436

3.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 4.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

Review 5.  Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Authors:  Maria Eliza Freitas; Christopher W Hess; Susan H Fox
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 6.  Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease.

Authors:  S DeVaughn; E M Müller-Oehring; B Markey; H M Brontë-Stewart; T Schulte
Journal:  Neuropsychol Rev       Date:  2015-11-17       Impact factor: 7.444

7.  Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-11

8.  Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.

Authors:  Jong-Suep Baek; Jie Kai Tee; Yi Yun Pang; Ern Yu Tan; Kah Leong Lim; Han Kiat Ho; Say Chye Joachim Loo
Journal:  Neuromolecular Med       Date:  2018-04-25       Impact factor: 3.843

Review 9.  Treatment strategies for Parkinson's disease.

Authors:  Hong Yuan; Zhen-Wen Zhang; Li-Wu Liang; Quan Shen; Xiang-Dang Wang; Su-Mei Ren; Hong-Jie Ma; Shu-Jun Jiao; Ping Liu
Journal:  Neurosci Bull       Date:  2010-02       Impact factor: 5.203

Review 10.  Efficacy and safety of Tai Chi for Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Xiaojia Ni; Shaonan Liu; Fuchang Lu; Xiaogeng Shi; Xinfeng Guo
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.